On Tuesday, Edison International (NYSE:EIX)’s shares inclined 1.4% to $57.78
Edison International to Present at the Barclays CEO Energy-Power Conference 2015
WHAT: Edison International to present at the Barclays CEO Energy-Power Conference 2015
WHO: Jim Scilacci Executive Vice President and Chief Financial Officer Edison International
WHEN: Wednesday, September 9, 2015 1:05 p.m. (Eastern Daylight Time)
Edison International, through its auxiliaries, generates and supplies electricity. The company generates electricity through hydroelectric, diesel, natural gas, nuclear, and photovoltaic sources. It supplies electricity primarily to commercial, residential, agricultural and other, industrial, and public authorities through transmission and distribution netoperates.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s shares gained 0.02% to $233.84.
Biotech company Pharming Group N.V. published its (unaudited) financial report for the six months ended 30 June 2015.
FINANCIAL HIGHLIGHTS
- Revenues from operations raised to €5.2 million (H1 2014: €2.5 million) as a result of substantially raised revenues from product sales of €4.1 million (€2.9 million for Q2), contrast to €1.4 million for H1 2014. Revenues from Ruconest® sales in the US amounted to €3.0 million (€2.4 million for Q2) and in the EU amounted to €1.1 million (€0.5 million for Q2).
- Gross profit raised to €2.9 million (€2.1 million for Q2) from €0.7 million in H1 2014 as a result of sales in the US and a gain on inventory impairments, reflecting the improving yields from sales in the US and direct commercialization in the EU.
- As result of increasing costs of operations (R&D, General and Administrative and Marketing and Sales), operating result reduced by €0.7 million, to a loss of €6.1 million contrast to a €5.4 million loss for H1 2014. The enhance is mostly a result of the (non-cash) share-based compensation.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
At the end of Tuesday’s trade, SLM Corp (NASDAQ:SLM)‘s shares surged 1.66% to $7.96.
Sallie Mae (SLM), the nation’s saving, planning, and paying for college company, recently declared Chairman and Chief Executive Officer Raymond J. Quinlan will speak at the 2015 Barclays Global Financial Services Conference on Wednesday, Sept. 16, at 8:15 a.m. EDT.
SLM Corporation, together with its auxiliaries, operates as a saving, planning, and paying for education company in the United States. The company offers private education loans to students and their families. It also provides banking products, such as high yield savings accounts, money market accounts, and certificates of deposits; and operates a consumer savings network that offers financial rewards on everyday purchases to assist families save for college. SLM Corporation was founded in 1972 and is headquartered in Newark, Delaware.
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH), ended its Tuesday’s trading session with 3.54% gain, and closed at $44.78.
Tetraphase Pharmaceuticals, Inc. (TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, recently declared the appointment of Jacques Dumas, Ph.D. as Chief Scientific Officer.
Dr. Dumas joins Tetraphase from Merck Research Laboratories where he served as Vice President, Idenix, related to his preceding role as Chief Scientific Officer at Idenix Pharmaceuticals. From 2007 to 2014, Jacques worked for AstraZeneca, most recently as Vice President and Head of Strategy, Infection Innovative Medicines. In this role, he was responsible for disease area strategy and external collaborations for AstraZeneca’s small molecule infectious disease unit. Preceding to AstraZeneca, Jacques worked at Bayer Healthcare for 15 years, most recently as Director of Medicinal Chemistry. Jacques received his Ph.D. in Organic Chemistry from Paris IV University in France and accomplished a Postdoctoral Fellowship at Stanford University.
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections. Its lead product candidate comprises eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, counting multidrug-resistant Gram-negative infections.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
